This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mammography World Markets

Table 5.1: DR System Comparisons 68

Table 5.2: Average Mean Glandular Dose per Exposure According to Model 80

Table 5.3: Examination Dose According to Model 80

Table 5.4: Average MGD per Exposure in Screening and Clinical Use for Various Mammography Technologies and Vendors of FFDM 81

Table 6.1: Mammography Screening Prevalence Among Women 40 and Older in the U.S., 2010 84

Table 6.2: Mammography Screening Prevalence by Age and Poverty Status in the U.S., 1987-2010 85

Table 6.3: Certified Mammography Facilities and Accredited Units in the U.S., 2000-2011 86

Table 6.4: Prevalence of Screening Mammography in the U.S. by State, 2010 87

Table 6.5: Histologic Features of Breast Cancers Detected by SMP in BC, 2009 96

Table 6.6: Breast Cancer Screening Activity in the U.K., 2008-2010 102

Table 6.7: Acceptance of Breast Screening Invitations by Age—All Invitation Types 102

Table 6.8: Acceptance by Type of Screen: Women Aged 45-74 103

Table 6.9: Screening Quality—First Screen after First Invitation 103

Table 6.10: Screening Quality—Subsequent Screening 104

Table 6.11: Screening—Women Aged 71 and Over in the U.K. 104

Table 6.12: Assessment Outcomes—Age 50-70 104

Table 6.13: Assessment Outcomes—Age 45-74 in the U.K. 105

Table 6.14: Medicare Benefits Schedule-Funded Mammography Services in Australia, 2011 110

Table 6.15: Hospitalization for Female Breast Cancer in Australia, 2009-2010 111

Table 6.16: Same-Day Hospitalizations and Overnight Hospitalizations for Female Breast Cancer in Australia, 2009-2010 112

Table 7.1: Certified Mammography Facilities and Accredited Units in the U.S., 2000-2011 117

Table A2.1: Staging of Breast Cancer 139

Table A6.1: Estimated Number of Cancer Survivors in the U.S. as of January 1, 2012 160

Table A6.2: Estimated Numbers of U.S. Cancer Survivors by Site as of January 1, 2012 161

Table A6.3: Estimated U.S. Cancer Survivors by Sex and Time since Diagnosis as of January 1, 2012 161

Table A6.4: Estimated U.S. Cancer Survivors by Sex and Age as of January 1, 2012 162

Table A8.1: Mammography Reimbursement Rates—All Sites of Services 206

13 of 14

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,041.54 -190.48 -1.04%
S&P 500 2,104.20 -21.86 -1.03%
NASDAQ 5,032.7510 -56.6110 -1.11%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs